19F/177Lu-rhPSMA-7.3与177Lu-PSMA I&T在转移性去势抵抗性前列腺癌中的临床前比较:生物分布、剂量学与内放射治疗
该临床前研究在LNCaP和C4-2肿瘤荷瘤SCID小鼠中比较了19F/177Lu-rhPSMA-7.3与177Lu-PSMA I&T的生物分布、剂量学和治疗效果。结果显示19F/177Lu-rhPSMA-7.3具有更快的血液清除、更高的肿瘤摄取和滞留,以及更高的肿瘤吸收剂量,同时大多数器官的吸收剂量较低。单次30 MBq剂量下,19F/177Lu-rhPSMA-7.3相比177Lu-PSMA I&T显著缩小肿瘤并改善生存。
要点
- 19F/177Lu-rhPSMA-7.3肿瘤摄取更高、滞留更长,肿瘤剂量高于177Lu-PSMA I&T。
- 19F/177Lu-rhPSMA-7.3在大多数器官的吸收剂量低于177Lu-PSMA I&T。
- 单次30 MBq的19F/177Lu-rhPSMA-7.3较177Lu-PSMA I&T显著缩小肿瘤并提高6周生存。
核心结论
- 19F/177Lu-rhPSMA-7.3具有与177Lu-PSMA I&T相似的清除动力学和健康器官辐射剂量,但肿瘤摄取和滞留更优,可考虑临床转化。
- 初步治疗实验显示19F/177Lu-rhPSMA-7.3具有有利的抗肿瘤反应。
研究设计与样本
- 在LNCaP肿瘤荷瘤SCID小鼠中于注射后至7天的设定时间点处死(n=5)测定19F/177Lu-rhPSMA-7.3与177Lu-PSMA I&T的生物分布,并用OLINDA/EXM 1.0计算剂量学。
- 在C4-2肿瘤荷瘤SCID小鼠中比较单次30 MBq的19F/177Lu-rhPSMA-7.3(n=7)与177Lu-PSMA I&T治疗组(n=7)及对照组(n=6-7)的肿瘤生长和6周生存。
主要发现
- 19F/177Lu-rhPSMA-7.3血液清除快,注射后1小时血液摄取为0.63 %ID/g。
- 注射后1小时脾和肾摄取最高,分别为33.25 %ID/g和207.6 %ID/g,提示经肾排泄。
- 与177Lu-PSMA I&T相比,19F/177Lu-rhPSMA-7.3在LNCaP异种移植瘤中初始(1小时)肿瘤摄取高2.6倍,滞留更长(168小时时为4.5 %ID/g vs. 0.9 %ID/g)。
- 19F/177Lu-rhPSMA-7.3的肿瘤剂量显著更高(例如200 mm3时为7.47 vs. 1.96 µGy/MBq)。
- 大多数器官中177Lu-PSMA I&T的吸收剂量更高。
临床怎么用
- 临床前数据提示19F/177Lu-rhPSMA-7.3可作为诊疗一体化候选药物进一步临床转化评估。
- 其较高的肿瘤剂量和较低的多数器官剂量可能有利于提高治疗效果并降低正常组织毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are applicable as radiochemical twins for both diagnostic PET imaging and endoradiotherapy. On the basis of preliminary data as a diagnostic ligand, the isomer rhPSMA-7.3 is a promising candidate for potential endoradiotherapy. The aim of this preclinical evaluation was to assess the biodistribution, dosimetry, and therapeutic efficacy of 19F/177Lu-rhPSMA-7.3 in comparison to the established therapeutic agent 177Lu-PSMA I&T (imaging and therapy). Methods: The biodistribution of 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T was determined in LNCaP tumor-bearing severe combined immunodeficiency (SCID) mice after sacrifice at defined time points up to 7 d (n = 5). Organs and tumors were dissected, percentage injected dose per gram (%ID/g) was determined, and dosimetry was calculated using OLINDA/EXM, version 1.0. The therapeutic efficacy of a single 30-MBq dose of 19F/177Lu-rhPSMA-7.3 (n = 7) was compared with that of 177Lu-PSMA I&T in treatment groups (n = 7) and control groups (n = 6-7) using C4-2 tumor-bearing SCID mice by evaluating tumor growth and survival over 6 wk after treatment. Results: The biodistribution of 19F/177Lu-rhPSMA-7.3 revealed fast blood clearance (0.63 %ID/g at 1 h after injection), and the highest activity uptake was in the spleen and kidneys, particularly in the first hour (33.25 %ID/g and 207.6 %ID/g, respectively, at 1 h after injection), indicating a renal excretion pathway. Compared with 177Lu-PSMA I&T, 19F/177Lu-rhPSMA-7.3 exhibited an initial (1 h) 2.6-fold higher tumor uptake in LNCaP xenografts and a longer retention (4.5 %ID/g vs. 0.9 %ID/g at 168 h). The tumor dose of 19F/177Lu-rhPSMA-7.3 was substantially higher (e.g., 7.47 vs. 1.96 µGy/MBq at 200 mm3) than that of 177Lu-PSMA I&T. In most organs, absorbed doses were higher for 177Lu-PSMA I&T. A significantly greater tumor size reduction was shown for a single dose of 19F/177Lu-rhPSMA-7.3 than for 177Lu-PSMA I&T at the end of the experiment (P = 0.0167). At the predefined termination of the experiment at 6 wk, 7 of 7 and 3 of 7 mice were still alive in the 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T groups, respectively, compared with the respective control groups, with 0 of 7 and 0 of 6 mice. Conclusion: Compared with 177Lu-PSMA I&T, 19F/177Lu-rhPSMA-7.3 can be considered a suitable candidate for clinical translation because it has similar clearance kinetics and a similar radiation dose to healthy organs but superior tumor uptake and retention. Preliminary treatment experiments showed a favorable antitumor response.
引用
- Yusufi N, Wurzer A, Herz M, et al. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T. J Nucl Med. 2020. PMID: 33443072. doi:10.2967/jnumed.120.254516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。